PALACE 3 Study: Apremilast Shows 52 Wk. Efficacy in Active Psoriatic Arthritis
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.


